Dr. McGregor Discusses the Future of Treatment for RCC

Bradley McGregor, MD
Published: Monday, Sep 18, 2017



Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma (RCC).

Considering recent data with combinations such as axitinib (Inlyta) plus avelumab (Bavencio), and lenvatinib (Lenvima) plus pembrolizumab (Keytruda), McGregor believes that combinations in RCC will be moving toward the frontline setting.

Multiple trials are ongoing to determine what that combination will be.
 
SELECTED
LANGUAGE


Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma (RCC).

Considering recent data with combinations such as axitinib (Inlyta) plus avelumab (Bavencio), and lenvatinib (Lenvima) plus pembrolizumab (Keytruda), McGregor believes that combinations in RCC will be moving toward the frontline setting.

Multiple trials are ongoing to determine what that combination will be.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x